Peringatan Keamanan

Patients with severe renal impairment (with creatinine clearance below 30 mL/min) should avoid use of drug as their clearance of the drug is reduced and there is inconsistent evidence about its safety in this subset of patients.

Sugammadex

DB06206

small molecule approved

Deskripsi

Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.

Struktur Molekul 2D

Berat 2002.12
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) About 2 hours
Volume Distribusi At steady state, the volume of distribution is 11-14 L in adult patients with normal renal function.
Klirens (Clearance) 88L/min

Absorpsi

Sugammadex is administered intravenously.

Metabolisme

No metabolites of sugammadex were observed during clinical studies.

Rute Eliminasi

Renal excretion of unchanged product. >90 of dose is excreted within 24 hours. 0.02% is excreted in feces and air.

Interaksi Obat

105 Data
Lepirudin The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Sugammadex.
Bivalirudin The risk or severity of bleeding and hemorrhage can be increased when Bivalirudin is combined with Sugammadex.
Alteplase The risk or severity of bleeding and hemorrhage can be increased when Alteplase is combined with Sugammadex.
Urokinase The risk or severity of bleeding and hemorrhage can be increased when Urokinase is combined with Sugammadex.
Reteplase The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Sugammadex.
Anistreplase The risk or severity of bleeding and hemorrhage can be increased when Anistreplase is combined with Sugammadex.
Tenecteplase The risk or severity of bleeding and hemorrhage can be increased when Tenecteplase is combined with Sugammadex.
Abciximab The risk or severity of bleeding and hemorrhage can be increased when Abciximab is combined with Sugammadex.
Drotrecogin alfa The risk or severity of bleeding and hemorrhage can be increased when Drotrecogin alfa is combined with Sugammadex.
Streptokinase The risk or severity of bleeding and hemorrhage can be increased when Streptokinase is combined with Sugammadex.
Dicoumarol The risk or severity of bleeding and hemorrhage can be increased when Dicoumarol is combined with Sugammadex.
Argatroban The risk or severity of bleeding and hemorrhage can be increased when Argatroban is combined with Sugammadex.
Ardeparin The risk or severity of bleeding and hemorrhage can be increased when Ardeparin is combined with Sugammadex.
Phenindione The risk or severity of bleeding and hemorrhage can be increased when Phenindione is combined with Sugammadex.
Fondaparinux The risk or severity of bleeding and hemorrhage can be increased when Fondaparinux is combined with Sugammadex.
Warfarin The risk or severity of bleeding and hemorrhage can be increased when Warfarin is combined with Sugammadex.
Pentosan polysulfate The risk or severity of bleeding and hemorrhage can be increased when Pentosan polysulfate is combined with Sugammadex.
Phenprocoumon The risk or severity of bleeding and hemorrhage can be increased when Phenprocoumon is combined with Sugammadex.
Dipyridamole The risk or severity of bleeding and hemorrhage can be increased when Dipyridamole is combined with Sugammadex.
Heparin The risk or severity of bleeding and hemorrhage can be increased when Heparin is combined with Sugammadex.
Enoxaparin The risk or severity of bleeding and hemorrhage can be increased when Enoxaparin is combined with Sugammadex.
Epoprostenol The risk or severity of bleeding and hemorrhage can be increased when Epoprostenol is combined with Sugammadex.
Acenocoumarol The risk or severity of bleeding and hemorrhage can be increased when Acenocoumarol is combined with Sugammadex.
4-hydroxycoumarin The risk or severity of bleeding and hemorrhage can be increased when 4-hydroxycoumarin is combined with Sugammadex.
Coumarin The risk or severity of bleeding and hemorrhage can be increased when Coumarin is combined with Sugammadex.
Ximelagatran The risk or severity of bleeding and hemorrhage can be increased when Ximelagatran is combined with Sugammadex.
Desmoteplase The risk or severity of bleeding and hemorrhage can be increased when Desmoteplase is combined with Sugammadex.
Defibrotide The risk or severity of bleeding and hemorrhage can be increased when Defibrotide is combined with Sugammadex.
Ancrod The risk or severity of bleeding and hemorrhage can be increased when Ancrod is combined with Sugammadex.
Beraprost The risk or severity of bleeding and hemorrhage can be increased when Beraprost is combined with Sugammadex.
Prasugrel The risk or severity of bleeding and hemorrhage can be increased when Prasugrel is combined with Sugammadex.
Rivaroxaban The risk or severity of bleeding and hemorrhage can be increased when Rivaroxaban is combined with Sugammadex.
Sulodexide The risk or severity of bleeding and hemorrhage can be increased when Sulodexide is combined with Sugammadex.
Semuloparin The risk or severity of bleeding and hemorrhage can be increased when Semuloparin is combined with Sugammadex.
Idraparinux The risk or severity of bleeding and hemorrhage can be increased when Idraparinux is combined with Sugammadex.
Cangrelor The risk or severity of bleeding and hemorrhage can be increased when Cangrelor is combined with Sugammadex.
Astaxanthin The risk or severity of bleeding and hemorrhage can be increased when Astaxanthin is combined with Sugammadex.
Apixaban The risk or severity of bleeding and hemorrhage can be increased when Apixaban is combined with Sugammadex.
Otamixaban The risk or severity of bleeding and hemorrhage can be increased when Otamixaban is combined with Sugammadex.
Amediplase The risk or severity of bleeding and hemorrhage can be increased when Amediplase is combined with Sugammadex.
Dabigatran etexilate The risk or severity of bleeding and hemorrhage can be increased when Dabigatran etexilate is combined with Sugammadex.
Danaparoid The risk or severity of bleeding and hemorrhage can be increased when Danaparoid is combined with Sugammadex.
Dalteparin The risk or severity of bleeding and hemorrhage can be increased when Dalteparin is combined with Sugammadex.
Tinzaparin The risk or severity of bleeding and hemorrhage can be increased when Tinzaparin is combined with Sugammadex.
(R)-warfarin The risk or severity of bleeding and hemorrhage can be increased when (R)-warfarin is combined with Sugammadex.
Ethyl biscoumacetate The risk or severity of bleeding and hemorrhage can be increased when Ethyl biscoumacetate is combined with Sugammadex.
Nadroparin The risk or severity of bleeding and hemorrhage can be increased when Nadroparin is combined with Sugammadex.
Triflusal The risk or severity of bleeding and hemorrhage can be increased when Triflusal is combined with Sugammadex.
Ticagrelor The risk or severity of bleeding and hemorrhage can be increased when Ticagrelor is combined with Sugammadex.
Ditazole The risk or severity of bleeding and hemorrhage can be increased when Ditazole is combined with Sugammadex.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Sugammadex.
Edoxaban The risk or severity of bleeding and hemorrhage can be increased when Edoxaban is combined with Sugammadex.
Sodium citrate The risk or severity of bleeding and hemorrhage can be increased when Sodium citrate is combined with Sugammadex.
Dextran The risk or severity of bleeding and hemorrhage can be increased when Dextran is combined with Sugammadex.
Bemiparin The risk or severity of bleeding and hemorrhage can be increased when Bemiparin is combined with Sugammadex.
Parnaparin The risk or severity of bleeding and hemorrhage can be increased when Parnaparin is combined with Sugammadex.
Desirudin The risk or severity of bleeding and hemorrhage can be increased when Desirudin is combined with Sugammadex.
Antithrombin Alfa The risk or severity of bleeding and hemorrhage can be increased when Antithrombin Alfa is combined with Sugammadex.
Protein C The risk or severity of bleeding and hemorrhage can be increased when Protein C is combined with Sugammadex.
Antithrombin III human The risk or severity of bleeding and hemorrhage can be increased when Antithrombin III human is combined with Sugammadex.
Letaxaban The risk or severity of bleeding and hemorrhage can be increased when Letaxaban is combined with Sugammadex.
Darexaban The risk or severity of bleeding and hemorrhage can be increased when Darexaban is combined with Sugammadex.
Betrixaban The risk or severity of bleeding and hemorrhage can be increased when Betrixaban is combined with Sugammadex.
Nafamostat The risk or severity of bleeding and hemorrhage can be increased when Nafamostat is combined with Sugammadex.
Monteplase The risk or severity of bleeding and hemorrhage can be increased when Monteplase is combined with Sugammadex.
Gabexate The risk or severity of bleeding and hemorrhage can be increased when Gabexate is combined with Sugammadex.
Fluindione The risk or severity of bleeding and hemorrhage can be increased when Fluindione is combined with Sugammadex.
Protein S human The risk or severity of bleeding and hemorrhage can be increased when Protein S human is combined with Sugammadex.
Brinase The risk or severity of bleeding and hemorrhage can be increased when Brinase is combined with Sugammadex.
Clorindione The risk or severity of bleeding and hemorrhage can be increased when Clorindione is combined with Sugammadex.
Diphenadione The risk or severity of bleeding and hemorrhage can be increased when Diphenadione is combined with Sugammadex.
Tioclomarol The risk or severity of bleeding and hemorrhage can be increased when Tioclomarol is combined with Sugammadex.
Melagatran The risk or severity of bleeding and hemorrhage can be increased when Melagatran is combined with Sugammadex.
Saruplase The risk or severity of bleeding and hemorrhage can be increased when Saruplase is combined with Sugammadex.
(S)-Warfarin The risk or severity of bleeding and hemorrhage can be increased when (S)-Warfarin is combined with Sugammadex.
Tocopherylquinone The risk or severity of bleeding and hemorrhage can be increased when Tocopherylquinone is combined with Sugammadex.
Dabigatran The risk or severity of bleeding and hemorrhage can be increased when Dabigatran is combined with Sugammadex.
Troxerutin The risk or severity of bleeding and hemorrhage can be increased when Troxerutin is combined with Sugammadex.
Edetic acid The risk or severity of bleeding and hemorrhage can be increased when Edetic acid is combined with Sugammadex.
Reviparin The risk or severity of bleeding and hemorrhage can be increased when Reviparin is combined with Sugammadex.
Dermatan sulfate The risk or severity of bleeding and hemorrhage can be increased when Dermatan sulfate is combined with Sugammadex.
SR-123781A The risk or severity of bleeding and hemorrhage can be increased when SR-123781A is combined with Sugammadex.
Desogestrel The serum concentration of Desogestrel can be decreased when it is combined with Sugammadex.
Megestrol acetate The serum concentration of Megestrol acetate can be decreased when it is combined with Sugammadex.
Levonorgestrel The serum concentration of Levonorgestrel can be decreased when it is combined with Sugammadex.
Medroxyprogesterone acetate The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Sugammadex.
Norethisterone The serum concentration of Norethisterone can be decreased when it is combined with Sugammadex.
Ethynodiol diacetate The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Sugammadex.
Norgestimate The serum concentration of Norgestimate can be decreased when it is combined with Sugammadex.
Drospirenone The serum concentration of Drospirenone can be decreased when it is combined with Sugammadex.
Cyproterone acetate The serum concentration of Cyproterone acetate can be decreased when it is combined with Sugammadex.
Gestodene The serum concentration of Gestodene can be decreased when it is combined with Sugammadex.
Hydroxyprogesterone caproate The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Sugammadex.
Dienogest The serum concentration of Dienogest can be decreased when it is combined with Sugammadex.
Norethynodrel The serum concentration of Norethynodrel can be decreased when it is combined with Sugammadex.
Norgestrel The serum concentration of Norgestrel can be decreased when it is combined with Sugammadex.
Gestrinone The serum concentration of Gestrinone can be decreased when it is combined with Sugammadex.
Lynestrenol The serum concentration of Lynestrenol can be decreased when it is combined with Sugammadex.
Chlormadinone The serum concentration of Chlormadinone can be decreased when it is combined with Sugammadex.
Norgestrienone The serum concentration of Norgestrienone can be decreased when it is combined with Sugammadex.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17312211
    Naguib M: Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007 Mar;104(3):575-81.
  • PMID: 24098155
    Schaller SJ, Fink H: Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evid. 2013;8:57-67. doi: 10.2147/CE.S35675. Epub 2013 Sep 25.
  • PMID: 25885973
    Nag K, Singh DR, Shetti AN, Kumar H, Sivashanmugam T, Parthasarathy S: Sugammadex: A revolutionary drug in neuromuscular pharmacology. Anesth Essays Res. 2013 Sep-Dec;7(3):302-6. doi: 10.4103/0259-1162.123211.

Contoh Produk & Brand

Produk: 34 • International brands: 0
Produk
  • Bridion
    Injection, solution • 100 mg/1mL • Intravenous • US • Approved
  • Bridion
    Injection, solution • 100 mg/1mL • Intravenous • US • Approved
  • Bridion
    Injection, solution • 100 mg/1mL • Intravenous • US • Approved
  • Bridion
    Solution • 100 mg / mL • Intravenous • Canada • Approved
  • Bridion
    Injection, solution • 100 mg/ml • Intravenous • EU • Approved
  • Bridion
    Injection, solution • 100 mg/ml • Intravenous • EU • Approved
  • PMS-sugammadex
    Solution • 100 mg / mL • Intravenous • Canada • Generic • Approved
  • Sugammadex
    Injection • 500 mg/5mL • Not applicable • US
Menampilkan 8 dari 34 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul